Table 4 Breast cancer mortality according to HMGCR expression in crude and adjusted models.

From: Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study

All patients

Total (n)

Events (n)

Crude

Model 1

Model 2

Model 3

657

110

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

HMGCR negative

119

20

 

ref

0.33

 

ref

0.33

 

ref

0.45

 

ref

0.56

HMGCR weak

354

52

1.04

0.62–1.74

0.90

1.04

0.62–1.74

0.90

1.21

0.70–2.10

0.49

1.17

0.67–2.06

0.58

HMGCR moderate/strong

184

38

1.39

0.80–2.39

0.24

1.39

0.80–2.39

0.24

1.47

0.80–2.68

0.21

1.41

0.75–2.63

0.29

  1. Crude: unadjusted analysis; Model 1: adjusted for age; Model 2: adjusted for age, tumor size, tumor grade, lymph node involvement and ER status. Model 3: Model 2 and planned adjuvant treatment (chemo-, endocrine- and radiation treatment). HMGCR: HMG-CoA reductase; HR: Hazard ratio; CI: Confidence interval.
Back to article page